Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Jul 20;18(1):898.
doi: 10.1186/s12889-018-5809-7.

Safety monitoring of ROTAVAC vaccine and etiological investigation of intussusception in India: study protocol

Collaborators, Affiliations
Multicenter Study

Safety monitoring of ROTAVAC vaccine and etiological investigation of intussusception in India: study protocol

Samarasimha Reddy et al. BMC Public Health. .

Abstract

Background: ROTAVAC, an indigenous rotavirus vaccine, was introduced in the universal immunization program of India in four states in 2016 and expanded to five more states in 2017. The clinical trial on efficacy of ROTAVAC did not detect an increased risk of intussusception, but the trial was not large enough to detect a small risk. This protocol paper describes the establishment and implementation of a surveillance system to monitor the safety of rotavirus vaccine and investigate the potential infectious etiologies of intussusception.

Methods: This is a multi-centric hospital-based active surveillance being conducted at 28 hospitals in nine states of India. Data gathered from surveillance will be used to assess the risk of intussusception after ROTAVAC administration and to determine the infectious etiologies of intussusception. For safety assessment of ROTAVAC vaccine, children aged less than two years with intussusception admitted at the sentinel hospitals are enrolled into surveillance, a case report form completed, and a copy of the vaccination card obtained. The risk of intussusception following rotavirus vaccination will be assessed using a self-controlled case-series design. The investigation for potential infectious etiologies of intussusception is through a matched case-control design. Children enrolled for the safety assessment serve as cases and for each case, an age, gender and location matched control is enrolled within 30 days of case enrollment. Stool specimens are obtained from cases and controls. All forms and specimens are sent to the referral laboratory for data entry, analysis, multiplexed molecular testing, and storage.

Discussion: Anticipated public health benefits of this surveillance include the generation of information useful to national government on safety of vaccine and to make future decisions on vaccine use through risk-benefit analysis. Investigating infectious agents may help to determine the potential infectious etiologies of intussusception.

Keywords: India; Infectious etiologies; Intussusception; ROTAVAC; Rotavirus vaccine; Self-controlled case series methods.

PubMed Disclaimer

Conflict of interest statement

Consent for publication

Not applicable

Competing interests

Venkata Raghava Mohan is an Associate Editor for BMC Public Health. The other authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Sentinel hospitals in intussusception surveillance in India. Legends: 1 Kurnool, 2 Kakinada, 3 Vishakhapatnam, 4 Tirupathi, 5 Cuttack, 6 SUM, Bhubaneswar, 7 KIMS, Bhubaneswar, 8 HITECH, Bhubaneswar, 9 Rohtak, 10 Mewat, 11 Chandigarh, 12 Jaipur, 13 Udaipur, 14 Jodhpur, 15 CMC, Vellore 16 GVMC, Vellore, 17 ICH, Chennai, 18 KKCTH, Chennai, 19 Madurai, 20 Coimbatore, 21 Puducherry, 22 Indore, 23 Jabalpur, 24 Lucknow, 25 Varanasi, 26 Gorakhpur, 27 Tezpur, 28 Guwahati. Source: Community Health and Training Center, Christian Medical College, Vellore
Fig. 2
Fig. 2
Taqman array card (TAC) for enteropathogen testing

References

    1. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, Agocs M, Serhan F, et al. Global, regional, and National Estimates of rotavirus mortality in children <5 years of age, 2000–2013. Clin Infect Dis. 2016;62:S96–105. doi: 10.1093/cid/civ1013. - DOI - PMC - PubMed
    1. John J, Sarkar R, Muliyil J, Bhandari N, Bhan MK, Kang G. Rotavirus gastroenteritis in India, 2011–2013: Revised estimates of disease burden and potential impact of vaccines. Vaccine. 2014;32(Supplement 1):A5–A9. doi: 10.1016/j.vaccine.2014.03.004. - DOI - PubMed
    1. WHO Rotavirus vaccines. WHO position paper – January 2013. Wkly Epidemiol Rec. 2013;88:49–64. - PubMed
    1. Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014;383:2136–2143. doi: 10.1016/S0140-6736(13)62630-6. - DOI - PMC - PubMed
    1. Shri JP Nadda launches Rotavirus vaccine as part of Universal Immunization Programme; terms it a “historic moment” [Internet]. Available from: http://pib.nic.in/newsite/PrintRelease.aspx?relid=138342 [cited 2018 Jun 17].

Publication types

Substances